Skip to main content
    C

    CytoMed Therapeutics Limited Ordinary Shares (GDTC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.77
    -0.06 (-6.68%)

    Market Cap: $9.90M

    Last updated: Nov 17, 2026 at 10:50 AM ET

    CytoMed Therapeutics Limited Ordinary Shares (GDTC) Financials: Revenue, Profit and Cash Flow

    Updated Jun 30, 2026. Financial statements from company filings, amounts in SGD.

    CytoMed Therapeutics Limited Ordinary Shares reported revenue of SGD 324.39K for the fiscal year ended Dec 31, 2025, up 366.7% from the year before. That year, net income was SGD -3.98M with a net margin of -1227.1%, operating cash flow was SGD -3.70M and free cash flow was SGD -4.40M. The quarter ended Jun 30, 2026 had revenue of SGD 157.29K and net income of SGD -1.77M.

    Revenue and Margins

    Over the 5 years to Dec 2025, revenue grew from SGD 44.92K, a compound annual rate of 48.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025324.39K+366.7%79.0%-1476.3%-1227.1%
    Dec 202469.50K-86.3%75.4%-5175.3%-3621.1%
    Dec 2023509.13K+39.3%-856.6%-856.6%-811.8%
    Dec 2022365.60K+334.3%-29.8%-640.0%-856.4%
    Dec 202184.18K+87.4%131.0%-1373.6%-2463.4%
    Dec 202044.92KN/A122.1%-2955.8%-4323.2%
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue324.39K69.50K509.13K365.60K84.18K44.92KN/A
    Cost of revenue67.99K17.12K4.36M109.04K3.50K4.63KN/A
    Gross profit256.39K52.38K-4.36M-109.04K110.29K54.84KN/A
    Research and development2.22M1.91M1.59M1.52M1.09M1.04M439.80K
    Operating income-4.79M-3.60M-4.36M-2.34M-1.16M-1.33M-651.88K
    Net income-3.98M-2.52M-4.13M-3.13M-2.07M-1.94M-858.75K
    EBITDA-3.57M-2.17M-3.70MN/AN/A-1.04M-429.06K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Revenue157.29K189.44K168.50K205.08K134.90K134.72K141.70K112.04K112.39KN/A111.96K142.25K
    Gross profit-2.05M165.78K-2.45M173.09K125.55K125.39K127.06K110.94K111.28K-38.23K110.77K-63.47K
    Operating income-2.05M-562.07K-2.45M-661.11K-651.54K-650.70K-519.00K-530.23K-531.87K-1.52M-437.61K-1.58M
    Net income-1.77M-885.23K-1.74M-868.35K-1.13M-1.12M-724.93K-1.10M-545.63K-1.46M-989.17K-1.08M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of SGD 429.10K by 1.67M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets7.98M10.07M12.40M5.25M6.10M3.82M2.94M
    Current assets3.66M6.00M10.12M2.51M3.29M1.47M549.01K
    Cash and equivalents2.10M4.97M9.02M1.59M2.52M887.22K374.42K
    Total liabilities1.13M1.02M1.13M4.66M3.50M3.35M1.01M
    Short-term debt60.45K45.90K40.36K3.76M2.71M2.37MN/A
    Long-term debt368.66K394.31K407.77K468.83K539.12K590.67KN/A
    Shareholder equity6.54M8.96M11.28M589.71K2.60M477.01K1.94M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets7.01M7.02M7.98M7.98M8.39M8.38M10.07M10.22M10.90M10.94M12.37M12.39M
    Total liabilities1.61M1.62M1.13M1.13M1.14M1.14M1.02M1.04M748.46K750.78K1.12M1.13M
    Cash and equivalents1.46M1.46M2.10M2.10M2.87M2.86M4.97M5.05M6.47M6.49M9.00M9.01M
    Shareholder equity4.97M4.97M6.54M6.54M7.17M7.16M8.97M9.10M10.16M10.19M11.25M11.27M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-3.70M-2.71M-3.54M-1.40M-1.72M-916.39KN/A
    Capital expenditures703.13K1.40M58.45K476.00KN/A245.26K1.19M
    Free cash flow-4.40M-4.11M-3.60M-1.88MN/A-1.16MN/A
    Investing cash flow929.28K1.13M-2.73M-475.51K-825.59K-492.33K-1.19M
    Financing cash flow208.65K-64.88K10.92M968.35K4.18M1.91M1.20M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow-1.66M-822.87K-2.05M-1.05M-1.48M-801.45K-788.76K-577.73K-579.46K-1.03M-750.10K-1.02M
    Capital expenditures186.92K93.23K297.96K145.03K335.28K174.31K248.75K454.84K456.25K30.37K20.62K8.57K
    Free cash flow-1.84M-916.10K-2.35M-1.19M-1.82M-975.75K-1.04M-1.03M-1.04M-1.06M-770.72K-1.03M
    Last 12 quarters

    Frequently Asked Questions About GDTC

    What is CytoMed Therapeutics Limited Ordinary Shares' annual revenue?

    CytoMed Therapeutics Limited Ordinary Shares reported revenue of SGD 324.39K for the fiscal year ended Dec 31, 2025.

    How fast is CytoMed Therapeutics Limited Ordinary Shares' revenue growing?

    Revenue was up 366.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -3.9%.

    Is CytoMed Therapeutics Limited Ordinary Shares profitable?

    No. CytoMed Therapeutics Limited Ordinary Shares reported net income of SGD -3.98M for the fiscal year ended Dec 31, 2025, with a net margin of -1227.1%.

    How much free cash flow does GDTC generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of SGD -3.70M minus capital expenditures of SGD 703.13K produced free cash flow of SGD -4.40M.

    How much debt does CytoMed Therapeutics Limited Ordinary Shares have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of SGD 368.66K, short-term debt of SGD 60.45K and cash and equivalents of SGD 2.10M.